Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15469193 | 1.00 | HSD17B10 (0.43) | HSD17B10CYP1A2SLC7A5PTGS1PKM | |
| SCHEMBL20339346 | 1.00 | HSD17B10 (0.43) | HSD17B10CYP1A2SLC7A5PTGS1PKM | |
| SCHEMBL15511517 | 0.82 | SLC7A5 (0.41) | HSD17B10CYP1A2SLC7A5PTGS1PKM | |
| SCHEMBL29373039 | 0.82 | SLC7A5 (0.41) | HSD17B10CYP1A2SLC7A5PTGS1PKM | |
| SCHEMBL15469201 | 0.82 | SLC7A5 (0.41) | HSD17B10CYP1A2SLC7A5PTGS1PKM | |
| SCHEMBL20339996 | 0.80 | CYP1A2 (0.39) | HSD17B10CYP1A2SLC7A5PTGS1PKM | |
| SCHEMBL23069027 | 0.80 | NOS3 (0.55) | HSD17B10SLC7A5PTGS1PKMALPI | |
| SCHEMBL23069024 | 0.80 | NOS3 (0.55) | HSD17B10SLC7A5PTGS1PKMALPI | |
| SCHEMBL18995811 | 0.79 | HSD17B10 (0.51) | HSD17B10CYP1A2SLC7A5PTGS1PKM | |
| SCHEMBL17814914 | 0.79 | SLC7A5 (0.57) | HSD17B10CYP1A2SLC7A5PTGS1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025076210-A1 | CHLAMYDIA VACCINE COMPOSITIONS | VAXCYTE, INC. (US) | 2025-04-10 | — | — | WO | claimed |
| US-20240358823-A1 | CONJUGATED VACCINE CARRIER PROTEINS | VAXCYTE, INC. | 2024-10-31 | — | — | US | claimed |
| CN-118662649-A | Polypeptide-antigen conjugates with unnatural amino acids | VAXCYTE公司 | 2024-09-20 | — | — | CN | claimed |
| CN-117479961-A | Purification method of polysaccharide and polypeptide conjugate thereof | VAXCYTE公司 | 2024-01-30 | — | — | CN | claimed |
| EP-4294452-A1 | PURIFICATION PROCESSES FOR POLYSACCHARIDES AND POLYPEPTIDE CONJUGATES THEREOF | VAXCYTE, INC. (US) | 2023-12-27 | — | — | EP | claimed |
| EP-4106807-A1 | GROUP A STREP IMMUNOGENIC COMPOSITIONS WITH POLYSACCHARIDE-PROTEIN CONJUGATES | VAXCYTE, INC. (US) | 2022-12-28 | — | — | EP | claimed |
| CN-115175697-A | Group A streptococcus immunogenic compositions with polysaccharide-protein conjugates | VAXCYTE公司 | 2022-10-11 | — | — | CN | claimed |
| WO-2022178015-A1 | PURIFICATION PROCESSES FOR POLYSACCHARIDES AND POLYPEPTIDE CONJUGATES THEREOF | VAXCYTE, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| EP-3946443-A1 | OPTIMIZED CELL-FREE SYNTHESIS OF INVASION PLASMID ANTIGEN B AND RELATED COMPOSITIONS AND METHODS OF USE | VAXCYTE, INC. (US) | 2022-02-09 | — | — | EP | claimed |
| CN-114025789-A | Optimized cell-free synthesis of invasive plasmid antigen B and related compositions and methods of use | VAXCYTE公司 | 2022-02-08 | — | — | CN | claimed |
| EP-4689127-A1 | RF1 KO E. COLI STRAINS | Sutro Biopharma, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025090513-A1 | SHIGELLA VACCINE COMPOSITIONS | VAXCYTE, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025076210-A1 | CHLAMYDIA VACCINE COMPOSITIONS | VAXCYTE, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20240358823-A1 | CONJUGATED VACCINE CARRIER PROTEINS | VAXCYTE, INC. | 2024-10-31 | — | — | US | disclosed |
| US-20240342274-A1 | POLYPEPTIDE-ANTIGEN CONJUGATES WITH NON-NATURAL AMINO ACIDS | VAXCYTE, INC. | 2024-10-17 | — | — | US | disclosed |
| CN-115175697-A | Group A streptococcus immunogenic compositions with polysaccharide-protein conjugates | VAXCYTE公司 | 2022-10-11 | — | — | CN | disclosed |
| WO-2022178015-A1 | PURIFICATION PROCESSES FOR POLYSACCHARIDES AND POLYPEPTIDE CONJUGATES THEREOF | VAXCYTE, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| WO-2022040266-A1 | CARRIER-PROTEIN POLYSACCHARIDE CONJUGATION METHODS | VAXCYTE, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-3946443-A1 | OPTIMIZED CELL-FREE SYNTHESIS OF INVASION PLASMID ANTIGEN B AND RELATED COMPOSITIONS AND METHODS OF USE | VAXCYTE, INC. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-114025789-A | Optimized cell-free synthesis of invasive plasmid antigen B and related compositions and methods of use | VAXCYTE公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342274-A1 | POLYPEPTIDE-ANTIGEN CONJUGATES WITH NON-NATURAL AMINO ACIDS | CD74, DNPEP, NGLY1 | HSD17B10 3231/4885CYP1A2 4423/4885SLC7A5 227/4885 |
| US-20240358823-A1 | CONJUGATED VACCINE CARRIER PROTEINS | CD74, LY96, ASNS | HSD17B10 2269/4885CYP1A2 4136/4885SLC7A5 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.